The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst firm like Cantor Fitzgerald can instill confidence in investors about Vertex Pharmaceuticals' future prospects. This positive outlook is likely to influence the stock's short-term performance positively, as it reaffirms the company's strong position and potential for growth.